Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENESTgoal: Nilotinib for Treatment-free Remission in CML-CP
NCT01744665Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2013
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Aug 2013; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01744665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01744665.